Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension
Barnett, A. H., Patel, S., Harper, R., Toorawa, R., Thiemann, S., von Eynatten, M., Woerle, H.-J.Language:
english
Journal:
Diabetes, Obesity and Metabolism
DOI:
10.1111/dom.12011
Date:
September, 2012
File:
PDF, 619 KB
english, 2012